History of Changes for Study: NCT05930210

A Phase III Study to Evaluate Efficacy and Safety of ENERGI-F703 GEL in Subjects With Diabetic Foot Ulcers

A study version is represented by a row in the table.
Select two study versions to compare. One each from columns A and B.
Choose either the "Merged" or "Side-by-Side" comparison format to specify how the two study versions are to be displayed. The Side-by-Side format only applies to the Protocol section of the study.
Click "Compare" to do the comparison and show the differences.
Select a version's Submitted Date link to see a rendering of the study for that version.
The yellow A/B choices in the table indicate the study versions currently compared below. A yellow table row indicates the study version currently being viewed.
Hover over the "Recruitment Status" to see how the study's recruitment status changed.
Study edits or deletions are displayed in red.
Study additions are displayed in green.

Study Record Versions

Version	Submitted Date	Changes
1	June 25, 2023	None (earliest Version on record)
2	July 4, 2023	Arms and Interventions, Study Status and Study Identification
3	July 10, 2023	Contacts/Locations and Study Status
4	November 21, 2023	Contacts/Locations and Study Status

Comparison Format:

Merged
Side-by-Side

Study Identification


Unique Protocol ID:	ENERGI-F703-04
Brief Title:	A Phase III Study to Evaluate Efficacy and Safety of ENERGI-F703 GEL in Subjects With Diabetic Foot Ulcers
Official Title:	A Randomized, Double-Blind, Vehicle-controlled, Parallel, Phase III Study to Evaluate Efficacy and Safety of ENERGI-F703 GEL in Subjects With Diabetic Foot Ulcers
Secondary IDs:

Study Status


Record Verification:	June 2023
Overall Status:	Recruiting
Study Start:	May 30, 2023
Primary Completion:	July 31, 2024 [Anticipated]
Study Completion:	December 1, 2024 [Anticipated]

First Submitted:	June 15, 2023
First Submitted that Met QC Criteria:	June 25, 2023
First Posted:	July 5, 2023 [Actual]

Last Update Submitted that Met QC Criteria:	June 25, 2023
Last Update Posted:	July 5, 2023 [Actual]

Sponsor/Collaborators


Sponsor:	Energenesis Biomedical Co., Ltd.
Responsible Party:	Sponsor
Collaborators:

Oversight


U.S. FDA-regulated Drug:	Yes
U.S. FDA-regulated Device:	No
Data Monitoring:

Study Description

Brief Summary:

This Phase 3 study is a randomized, double-blind, vehicle-controlled, multiple-center, parallel study to evaluate efficacy and safety of ENERGI-F703 GEL compared with vehicle control in subjects with Wagner Grade 1 to Grade 2 diabetic foot ulcers. Baseline target ulcer size (<16 cm2 vs ≥16 cm2 ) will be included as a stratification factor. Subjects will be randomized 1:1 to receive ENERGI-F703 GEL or vehicle control using an interactive web response system for randomization to automatically assign a unique subject randomization number. Total duration of the study will be up to 31 weeks including Screening visit (approximately 2 to 3 weeks), double-blind dosing/observation phase (16 weeks), and a safety follow-up of 12 weeks after the last administration of study treatment.

Detailed Description:

Conditions


Conditions:	Diabetic Foot Ulcer Foot Ulcer Diabetes Mellitus Wound
Keywords:	Diabetic Foot Ulcer Diabetes Mellitus Wound Healing

Study Design


Study Type:	Interventional
Primary Purpose:	Treatment
Study Phase:	Phase 3
Interventional Study Model:	Parallel Assignment
Number of Arms:	2
Masking:	Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Allocation:	Randomized
Enrollment:	230 [Anticipated]

Arms and Interventions

Arms	Assigned Interventions
Experimental: ENERGI-F703 GEL	Drug: ENERGI-F703 GEL Standard of care and ENERGI-F703 GEL are applied for the treatment of diabetic foot ulcers.
Placebo Comparator: ENERGI-F703 matched vehicle	Drug: ENERGI-F703 matched vehicle Standard of care and ENERGI-F703 matched vehicle are applied for treatment of diabetic foot ulcers.

Outcome Measures


Primary Outcome Measures:
1.	The ulcer complete closure rate [ Time Frame: Weeks 16 ] Proportion of subjects with a recording of complete ulcer closure at Week 16 (the end of the treatment period) as assessed by the investigator, where such closure is subsequently confirmed at 2 consecutive study visits over a 2-week period (ie, by Week 18). A complete ulcer closure is defined as 100% skin re epithelialization without drainage or dressing requirements.
Secondary Outcome Measures:
1.	The time to ulcer closure [ Time Frame: Weeks 4, 6, 8, 10, 12, 14, and 16 ] Time to ulcer closure in weeks, defined as the time from randomization to first record of complete closure, as assessed by the investigator, where complete closure is subsequently confirmed at 2 consecutive study visits over a 2-week period
2.	The frequency and severity of adverse events [ Time Frame: Weeks 1, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 24, and 28 ] Frequency and severity of adverse events (AEs), including treatment emergent AEs, serious AEs, treatment-related AEs, and treatment-related serious AEs
3.	The proportion of subjects with complete ulcer closure [ Time Frame: Weeks 4, 6, 8, 10, 12, 14, and 16 ] Proportion of subjects with confirmed complete ulcer closure as assessed by the investigator.

Eligibility


Minimum Age:	18 Years
Maximum Age:
Sex:	All
Gender Based:
Accepts Healthy Volunteers:	No
Criteria:	Inclusion Criteria: Subject must be at least 18 years old. Subject must have diagnosed with diabetes mellitus (DM), eg, currently under DM medication treatment or subjects with naïve DM with duplicated hemoglobin A1c over 6.5% and fasting plasma glucose over 126 mg/dL measured at least 1 week apart before screening. Subject must have at least 1 cutaneous ulcer on the foot and not healing for at least 4 weeks. The largest diabetic foot ulcer will be selected as target ulcer. If 2 or more ulcers have the largest size, the one with worst grade will be selected. If 2 or more ulcers have the largest size and grade, the one with longest duration will be selected. The target ulcer is classified as Grade 1 to Grade 2 ulcer according to Wagner Grading System and with ulcer size of 1.5 cm2 to 25 cm2. Diabetic foot ulcers should be free of any necrosis or infection Subject has signed the written informed consent form Male subjects must be surgically sterile (biologically or surgically) or commit to the use of a reliable method of birth control (must agree to use double-barrier contraception in the event of sexual activity) or be practicing abstinence for the duration of the study and for 30 days after study treatment administration. Female subjects are eligible only if all of the following apply: Not pregnant with a negative serum pregnancy test at Screening visit and negative urine pregnancy test within 24 hours before randomization (test not required for females of non-childbearing potential, defined as surgically sterile [eg, hysterectomy or bilateral oophorectomy] or postmenopausal [amenorrheic for at least 1 year]) Not lactating Not planning to become pregnant during the study If of childbearing potential, commits to the use of a highly effective method of contraception for the duration of the study and at least 30 days after study treatment administration. Exclusion Criteria: History or evidence of osteomyelitis as confirmed by the investigator. An x-ray/pathology assessment of debridement or a probe-to-bone (PTB) test will be used to determine presence of osteomyelitis. With target ulcer size decreased by at least 30% after at least 2 weeks of standard of care-only period between screening and randomization Subjects with highly exudated wounds which require dressing changes more than 3 times a day may be enrolled, but heavily exudated wounds should not be selected as target ulcers With poor nutritional status (serum albumin <2g/dL or prealbumin <10 mg/dL), poor diabetic control (hemoglobin A1c >12%), a leukocyte counts <2,000/mm3, abnormal liver function (aspartate aminotransferase, alanine aminotransferase >3 x upper limit of normal range) within 21 days before Randomization visit Requiring treatment with systemic corticosteroids, immunosuppressive or chemotherapeutic agents With known or suspected hypersensitivity to any ingredients of study product and vehicle With coronary heart disease with myocardial infarction, coronary artery bypass graft, or percutaneous transluminal coronary angioplasty within 3 months prior to study Known or suspected history of drug abuse or a recent history of alcohol abuse (regularly drinks >4 units of alcohol per day: 1 unit = 8 oz. beer, 3 oz. wine, or 1 oz. spirits) within 6 months prior to screening History or positive test results for HIV, presence of active Hepatitis B virus (HBV), or active Hepatitis C virus (HCV) Hepatitis B surface antigen positive at screening is exclusionary Subjects with history of past or resolved HBV infection or hepatitis B core antibody positive at screening are eligible if HBV DNA viral load ≤2000 IU/mL in the absence of antiviral therapy and during the previous 12 weeks prior to the viral load evaluation with normal transaminases values Subjects with a history of HCV infection or HCV antibody positive at screening are eligible if HCV viral load is below the level of detection Malignancy in the last 2 years, with the exception of non-metastatic basal cell or squamous cell carcinoma of the skin or localized carcinoma in situ of the cervix Ankle brachial index <0.8 or >1.4 Enrollment in any investigational drug trial within 4 weeks before entering this study With any condition judged by the investigator that entering the trial may be detrimental to the subject -

Contacts/Locations


Locations:	United States, Florida
	Bioclinical Research [Recruiting] Miami, Florida, United States, 33155 Contact:Contact: Rogelio Iglesias, Dr. 305-264-6822 riglesias@biocresearch.com

IPDSharing


Plan to Share IPD:	Undecided

References


Citations:
Links:
Available IPD/Information: